Compounds > sec-butyl-propylacetamide
Page last updated: 2024-11-13

sec-butyl-propylacetamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

sec-butyl-propylacetamide: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID44550483
CHEMBL ID1079991
SCHEMBL ID1577854
MeSH IDM0571214

Synonyms (5)

Synonym
CHEMBL1079991
sec-butyl-propylacetamide
SCHEMBL1577854
sec-butylpropylacetamide
s-butyl-propylacetamide

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" This study describes synthesis and stereospecific comparative pharmacodynamics (PD, anticonvulsant activity and teratogenicity) and pharmacokinetic (PK) analysis of four individual SPD stereoisomers."( Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus.
Bialer, M; Finnell, RH; Hen, N; McDonough, JH; Shekh-Ahmad, T; Wlodarczyk, B; Yagen, B, 2013)		0.39
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (66)

Assay IDTitleYearJournalArticle
AID765806Anticonvulsant activity in ip dosed albino CF1 mouse assessed as protection against 32 mA-current- for 3 secs induced seizures after 0.25 to 0.5 hrs by 6Hz psychomotor seizure test2013Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus.
AID684370Anticonvulsant activity in ip dosed Sprague-Dawley albino rat assessed as protection against pilocarpine-induced status epilepticus after 0.5 hrs2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Syntheses and evaluation of anticonvulsant activity of novel branched alkyl carbamates.
AID470094Antiepileptic activity in CF1 mouse assessed as inhibition of subcutaneous pentylenetetrazole-induced seizures at 100 mg/kg, ip after 4 hrs2009Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22
Synthesis and evaluation of antiallodynic and anticonvulsant activity of novel amide and urea derivatives of valproic acid analogues.
AID765808Neurotoxicity in ip dosed albino CF1 mouse assessed as minimal motor impairment after 0.25 to 0.5 hrs2013Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus.
AID765795Protection against kainic acid-induced spontaneous electrographic seizures in combined medial entorhinal cortex hippocampal brain slices of albino Sprague-Dawley rat assessed as burst duration at 100 uM after 1 week relative to control2013Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus.
AID765798Neurotoxicity in po dosed albino Sprague-Dawley rat assessed as minimal motor impairment after 0.5 to 1 hr2013Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus.
AID765810Anticonvulsant activity in ip dosed albino CF1 mouse assessed as protection against subcutaneous metrazol-induced seizures after 0.25 to 0.5 hrs2013Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus.
AID765800Anticonvulsant activity in po dosed albino Sprague-Dawley rat assessed as protection against maximal electroshock-induced seizures after 0.5 to 1 hr2013Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus.
AID765804Anticonvulsant activity in ip dosed albino Sprague-Dawley rat assessed as protection against subcutaneous metrazol-induced seizures after 0.25 to 0.5 hrs2013Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus.
AID765809Anticonvulsant activity in ip dosed albino CF1 mouse assessed as protection against maximal electroshock-induced seizures after 0.25 to 0.5 hrs2013Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus.
AID1312142Anticonvulsant activity in ip dosed albino CF1 mouse assessed as protection against 6 Hz current-induced seizures by psychomotor test2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
Design and comparative anticonvulsant activity assessment of CNS-active alkyl-carbamoyl imidazole derivatives.
AID470091Antiepileptic activity in CF1 mouse assessed as inhibition of subcutaneous pentylenetetrazole-induced seizures at 100 mg/kg, ip after 0.5 hrs2009Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22
Synthesis and evaluation of antiallodynic and anticonvulsant activity of novel amide and urea derivatives of valproic acid analogues.
AID1312145Neurotoxicity in ip dosed albino CF1 mouse assessed as motor impairment by rotorod test2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
Design and comparative anticonvulsant activity assessment of CNS-active alkyl-carbamoyl imidazole derivatives.
AID765790Teratogenicity in SWV/Fnn mouse assessed as live fetuses at 283 mg/kg, ip on day 8.5 of gestation (Rvb = 93.7 %)2013Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus.
AID765783Teratogenicity in SWV/Fnn mouse assessed as fetuses with neural tube defects at 141 mg/kg, ip on day 8.5 of gestation relative to vehicle-treated control2013Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus.
AID470095Antiepileptic activity in CF1 mouse assessed as inhibition of subcutaneous pentylenetetrazole-induced seizures at 300 mg/kg, ip after 4 hrs2009Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22
Synthesis and evaluation of antiallodynic and anticonvulsant activity of novel amide and urea derivatives of valproic acid analogues.
AID765802Anticonvulsant activity in ip dosed albino Sprague-Dawley rat nerve agent seizure model assessed as termination of soman-induced electrographic and convulsive seizures administered 20 mins post seizure measured after 0.25 to 0.5 hrs2013Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus.
AID765779Anticonvulsant activity in ip dosed guinea pig assessed as protection against soman-induced electrographic and convulsive seizures administered 40 mins post seizure2013Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus.
AID765780Anticonvulsant activity in ip dosed rat assessed as protection against soman-induced electrographic and convulsive seizures administered 40 mins post seizure2013Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus.
AID1312144Protective index, ratio of TD50 for neurotoxicity in ip dosed albino CF1 mouse to ED50 for anticonvulsant activity in ip dosed 6 Hz current-induced seizure albino CF1 mouse model2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
Design and comparative anticonvulsant activity assessment of CNS-active alkyl-carbamoyl imidazole derivatives.
AID470102Antiallodynic activity in ip dosed rat assessed as protection against spinal nerve ligation-induced neuropathic pain2009Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22
Synthesis and evaluation of antiallodynic and anticonvulsant activity of novel amide and urea derivatives of valproic acid analogues.
AID470100Neurotoxicity in CF1 mouse assessed as protection against motor impairment at 100 mg/kg, ip after 4 hrs by rotarod test2009Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22
Synthesis and evaluation of antiallodynic and anticonvulsant activity of novel amide and urea derivatives of valproic acid analogues.
AID765777Solubility of the compound in water2013Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus.
AID1312143Anticonvulsant activity in ip dosed albino CF1 mouse assessed as protection against 6 Hz current-induced seizure by measuring time to peak effect2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
Design and comparative anticonvulsant activity assessment of CNS-active alkyl-carbamoyl imidazole derivatives.
AID470088Antiepileptic activity in CF1 mouse assessed as inhibition of maximal electroshock-induced seizures at 100 mg/kg, ip after 4 hrs2009Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22
Synthesis and evaluation of antiallodynic and anticonvulsant activity of novel amide and urea derivatives of valproic acid analogues.
AID470115Anticonvulsant activity in ip dosed albino Sprague-Dawley rat assessed as protection against pilocarpine-induced seizure2009Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22
Synthesis and evaluation of antiallodynic and anticonvulsant activity of novel amide and urea derivatives of valproic acid analogues.
AID470111Anticonvulsant activity in albino Sprague-Dawley rat assessed as protection against pilocarpine-induced seizure at 130 mg/kg, ip treated after 30 mins of pilcarpine challenge2009Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22
Synthesis and evaluation of antiallodynic and anticonvulsant activity of novel amide and urea derivatives of valproic acid analogues.
AID470099Neurotoxicity in CF1 mouse assessed as protection against motor impairment at 30 mg/kg, ip after 4 hrs by rotarod test2009Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22
Synthesis and evaluation of antiallodynic and anticonvulsant activity of novel amide and urea derivatives of valproic acid analogues.
AID765788Teratogenicity in SWV/Fnn mouse assessed as normal fetuses at 283 mg/kg, ip on day 8.5 of gestation (Rvb = 100 %)2013Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus.
AID765813AUC in rat at 60 mg/kg, ip2013Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus.
AID1312140Anticonvulsant activity in ip dosed albino CF1 mouse assessed as protection against maximal electroshock-induced seizures by measuring time to peak effect2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
Design and comparative anticonvulsant activity assessment of CNS-active alkyl-carbamoyl imidazole derivatives.
AID470103Antiepileptic activity in ip dosed CF1 mouse assessed as inhibition of maximal electroshock-induced seizures2009Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22
Synthesis and evaluation of antiallodynic and anticonvulsant activity of novel amide and urea derivatives of valproic acid analogues.
AID470096Neurotoxicity in CF1 mouse assessed as protection against motor impairment at 30 mg/kg, ip after 0.5 hrs by rotarod test2009Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22
Synthesis and evaluation of antiallodynic and anticonvulsant activity of novel amide and urea derivatives of valproic acid analogues.
AID765794Teratogenicity in SWV/Fnn mouse assessed as resorption at 283 mg/kg, ip on day 8.5 of gestation (Rvb = 6.3 %)2013Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus.
AID765801Neurotoxicity in ip dosed albino Sprague-Dawley rat assessed as minimal motor impairment after 0.25 to 0.5 hrs2013Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus.
AID470110Anticonvulsant activity in albino Sprague-Dawley rat assessed as protection against pilocarpine-induced seizure at 65 mg/kg, ip2009Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22
Synthesis and evaluation of antiallodynic and anticonvulsant activity of novel amide and urea derivatives of valproic acid analogues.
AID1312150Protective index, ratio of TD50 for neurotoxicity in ip dosed albino CF1 mouse to ED50 for protection against sound-induced seizures in ip dosed AGS-susceptible frings albino CF1 mouse2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
Design and comparative anticonvulsant activity assessment of CNS-active alkyl-carbamoyl imidazole derivatives.
AID765817Terminal half life in rat at 60 mg/kg, ip2013Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus.
AID765812Tmax in rat at 60 mg/kg, ip2013Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus.
AID1312139Protective index, ratio of TD50 for neurotoxicity in ip dosed albino CF1 mouse to ED50 for anticonvulsant activity in ip dosed maximal subcutaneous metrazol-induced seizure albino CF1 mouse model2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
Design and comparative anticonvulsant activity assessment of CNS-active alkyl-carbamoyl imidazole derivatives.
AID765807Anticonvulsant activity in ip dosed albino CF1 mouse assessed as protection against 44 mA-current- for 3 secs induced seizures after 0.25 to 0.5 hrs by 6Hz psychomotor seizure test2013Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus.
AID765799Anticonvulsant activity in po dosed albino Sprague-Dawley rat assessed as protection against subcutaneous metrazol-induced seizures after 0.5 to 1 hr2013Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus.
AID470092Antiepileptic activity in CF1 mouse assessed as inhibition of subcutaneous pentylenetetrazole-induced seizures at 300 mg/kg, ip after 0.5 hrs2009Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22
Synthesis and evaluation of antiallodynic and anticonvulsant activity of novel amide and urea derivatives of valproic acid analogues.
AID470087Antiepileptic activity in CF1 mouse assessed as inhibition of maximal electroshock-induced seizures at 30 mg/kg, ip after 4 hrs2009Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22
Synthesis and evaluation of antiallodynic and anticonvulsant activity of novel amide and urea derivatives of valproic acid analogues.
AID470090Antiepileptic activity in CF1 mouse assessed as inhibition of subcutaneous pentylenetetrazole-induced seizures at 30 mg/kg, ip after 0.5 hrs2009Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22
Synthesis and evaluation of antiallodynic and anticonvulsant activity of novel amide and urea derivatives of valproic acid analogues.
AID765784Teratogenicity in SWV/Fnn mouse assessed as fetuses with neural tube defects at 283 mg/kg, ip on day 8.5 of gestation relative to vehicle-treated control2013Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus.
AID765796Protection against kainic acid-induced spontaneous electrographic seizures in combined medial entorhinal cortex hippocampal brain slices of albino Sprague-Dawley rat assessed as burst rate at 100 uM after 1 week relative to control2013Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus.
AID765786Teratogenicity in SWV/Fnn mouse assessed as normal fetuses at 141 mg/kg, ip on day 8.5 of gestation (Rvb = 100 %)2013Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus.
AID765789Teratogenicity in SWV/Fnn mouse assessed as live fetuses at 141 mg/kg, ip on day 8.5 of gestation (Rvb = 93.7 %)2013Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus.
AID765815Apparent volume of distribution at steady state in rat at 60 mg/kg, ip2013Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus.
AID1312141Anticonvulsant activity in ip dosed albino CF1 mouse assessed as protection against subcutaneous metrazol-induced seizures by measuring time to peak effect2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
Design and comparative anticonvulsant activity assessment of CNS-active alkyl-carbamoyl imidazole derivatives.
AID470093Antiepileptic activity in CF1 mouse assessed as inhibition of subcutaneous pentylenetetrazole-induced seizures at 30 mg/kg, ip after 4 hrs2009Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22
Synthesis and evaluation of antiallodynic and anticonvulsant activity of novel amide and urea derivatives of valproic acid analogues.
AID1312149Anticonvulsant activity in ip dosed AGS-susceptible frings albino CF1 mouse assessed as protection against sound-induced seizures2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
Design and comparative anticonvulsant activity assessment of CNS-active alkyl-carbamoyl imidazole derivatives.
AID765814Cmax in rat at 60 mg/kg, ip2013Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus.
AID765778Solubility of the compound in 5:1:4 solution of propylene glycol, alcohol and water2013Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus.
AID765816Apparent clearance in rat at 60 mg/kg, ip2013Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus.
AID470084Antiepileptic activity in CF1 mouse assessed as inhibition of maximal electroshock-induced seizures at 30 mg/kg, ip after 0.5 hrs2009Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22
Synthesis and evaluation of antiallodynic and anticonvulsant activity of novel amide and urea derivatives of valproic acid analogues.
AID470086Antiepileptic activity in CF1 mouse assessed as inhibition of maximal electroshock-induced seizures at 300 mg/kg, ip after 0.5 hrs2009Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22
Synthesis and evaluation of antiallodynic and anticonvulsant activity of novel amide and urea derivatives of valproic acid analogues.
AID765792Teratogenicity in SWV/Fnn mouse assessed as resorption at 141 mg/kg, ip on day 8.5 of gestation (Rvb = 6.3 %)2013Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus.
AID470101Neurotoxicity in CF1 mouse assessed as protection against motor impairment at 300 mg/kg, ip after 4 hrs by rotarod test2009Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22
Synthesis and evaluation of antiallodynic and anticonvulsant activity of novel amide and urea derivatives of valproic acid analogues.
AID765805Anticonvulsant activity in ip dosed albino Sprague-Dawley rat assessed as protection against maximal electroshock-induced seizures after 0.25 to 0.5 hrs2013Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus.
AID1312138Anticonvulsant activity in ip dosed albino CF1 mouse assessed as protection against subcutaneous metrazol-induced seizures2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
Design and comparative anticonvulsant activity assessment of CNS-active alkyl-carbamoyl imidazole derivatives.
AID470097Neurotoxicity in CF1 mouse assessed as protection against motor impairment at 100 mg/kg, ip after 0.5 hrs by rotarod test2009Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22
Synthesis and evaluation of antiallodynic and anticonvulsant activity of novel amide and urea derivatives of valproic acid analogues.
AID765803Anticonvulsant activity in ip dosed albino Sprague-Dawley rat assessed as protection against pilocarpine-induced behavioral seizures administered 30 mins post seizure measured after 0.25 to 0.5 hrs2013Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus.
AID765811Mean residence time in rat at 60 mg/kg, ip2013Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus.
AID470089Antiepileptic activity in CF1 mouse assessed as inhibition of maximal electroshock-induced seizures at 300 mg/kg, ip after 4 hrs2009Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22
Synthesis and evaluation of antiallodynic and anticonvulsant activity of novel amide and urea derivatives of valproic acid analogues.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (7.14)29.6817
2010's13 (92.86)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 13.20

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index13.20 (24.57)
Research Supply Index2.71 (2.92)
Research Growth Index5.91 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (13.20)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (7.14%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (92.86%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
gamma-aminobutyric acid
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.. gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.		2.1510amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid		human metabolite;
neurotransmitter;
Saccharomyces cerevisiae metabolite;
signalling molecule
carbamazepine
Carbamazepine: A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties.. carbamazepine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine carrying a carbamoyl substituent at the azepine nitrogen, used as an anticonvulsant.		2.0710dibenzoazepine;
ureas		analgesic;
anticonvulsant;
antimanic drug;
drug allergen;
EC 3.5.1.98 (histone deacetylase) inhibitor;
environmental contaminant;
glutamate transporter activator;
mitogen;
non-narcotic analgesic;
sodium channel blocker;
xenobiotic
diazepam
Diazepam: A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of GAMMA-AMINOBUTYRIC ACID activity.. diazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a methyl group at position 1 and a phenyl group at position 5.		2.08101,4-benzodiazepinone;
organochlorine compound		anticonvulsant;
anxiolytic drug;
environmental contaminant;
sedative;
xenobiotic
valproic acid
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.. valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.		5.21140branched-chain fatty acid;
branched-chain saturated fatty acid		anticonvulsant;
antimanic drug;
EC 3.5.1.98 (histone deacetylase) inhibitor;
GABA agent;
neuroprotective agent;
psychotropic drug;
teratogenic agent
felbamate
Felbamate: A PEGylated phenylcarbamate derivative that acts as an antagonist of NMDA RECEPTORS. It is used as an anticonvulsant, primarily for the treatment of SEIZURES in severe refractory EPILEPSY.. felbamate : The bis(carbamate ester) of 2-phenylpropane-1,3-diol. An anticonvulsant, it is used in the treatment of epilepsy.		2.520carbamate esteranticonvulsant;
neuroprotective agent
gabapentin
Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.. gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.		2.1510gamma-amino acidanticonvulsant;
calcium channel blocker;
environmental contaminant;
xenobiotic
pentobarbital
Pentobarbital: A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Drug Evaluations Annual, 1994, p236). pentobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and sec-pentyl groups.		2.0810barbituratesGABAA receptor agonist
pilocarpine
Pilocarpine: A slowly hydrolyzed muscarinic agonist with no nicotinic effects. Pilocarpine is used as a miotic and in the treatment of glaucoma.. (+)-pilocarpine : The (+)-enantiomer of pilocarpine.		2.0810pilocarpineantiglaucoma drug
soman
Soman: An organophosphorus compound that inhibits cholinesterase. It causes seizures and has been used as a chemical warfare agent.		2.0810phosphonic ester
paraoxon
[no description available]		7.110aryl dialkyl phosphate;
organophosphate insecticide		EC 3.1.1.7 (acetylcholinesterase) inhibitor;
mouse metabolite
valnoctamide
[no description available]		4.5770fatty amide
nafimidone
nafimidone: RN given refers to parent cpd		2.1310
denzimol
denzimol: structure in first source		2.1310
dipropylacetamide
dipropylacetamide: structure. valpromide : A fatty amide derived from valproic acid.		2.0510fatty amidegeroprotector;
metabolite;
teratogenic agent
propylisopropylacetamide
propylisopropylacetamide: structure		2.0510
rwj-333369
S-2-O-carbamoyl-1-o-chlorophenyl-ethanol: neuromodulator/Antiepileptic Agent; structure in first source		2.0710organochlorine compound
valproate sodium
Epilim: oral sodium valproate used as antidepressive agent. sodium valproate : The sodium salt of valproic acid.. valproate : A branched-chain saturated fatty acid anion that is the conjugate base of valproic acid.		2.0810organic sodium saltgeroprotector
ConditionIndicatedRelationship StrengthStudiesTrials
Ache
[description not available]		02.4920
Absence Seizure
[description not available]		03.3360
Pain
An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.		07.4920
Seizures
Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.		08.3360
Encephalopathy, Toxic
[description not available]		02.0710
Absence Status
[description not available]		04.5180
Status Epilepticus
A prolonged seizure or seizures repeated frequently enough to prevent recovery between episodes occurring over a period of 20-30 minutes. The most common subtype is generalized tonic-clonic status epilepticus, a potentially fatal condition associated with neuronal injury and respiratory and metabolic dysfunction. Nonconvulsive forms include petit mal status and complex partial status, which may manifest as behavioral disturbances. Simple partial status epilepticus consists of persistent motor, sensory, or autonomic seizures that do not impair cognition (see also EPILEPSIA PARTIALIS CONTINUA). Subclinical status epilepticus generally refers to seizures occurring in an unresponsive or comatose individual in the absence of overt signs of seizure activity. (From N Engl J Med 1998 Apr 2;338(14):970-6; Neurologia 1997 Dec;12 Suppl 6:25-30)		04.5180
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		03.1950
DRESS Syndrome
[description not available]		02.0810
Innate Inflammatory Response
[description not available]		02.5220
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.5220
Acute Disease
Disease having a short and relatively severe course.		02.0810
Abdominal Migraine
[description not available]		02.1310
Migraine Disorders
A class of disabling primary headache disorders, characterized by recurrent unilateral pulsatile headaches. The two major subtypes are common migraine (without aura) and classic migraine (with aura or neurological symptoms). (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1)		02.1310
Nerve Pain
[description not available]		02.1510
Neuralgia
Intense or aching pain that occurs along the course or distribution of a peripheral or cranial nerve.		02.1510